tradingkey.logo
tradingkey.logo
Search

Metagenomi Inc

MGX
Add to Watchlist
1.130USD
-0.010-0.88%
Close 09-23 16:00ET
42.54MMarket Cap
LossP/E TTM

About Metagenomi Inc Company

Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.

Metagenomi Inc Profile

Ticker SymbolMGX
Company nameMetagenomi Inc
IPO dateFeb 09, 2024
CEOIrish (Jian)
Number of employees202
Security typeOrdinary Share
Fiscal year-endFeb 09
Address5959 Horton St
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15108714880
Websitehttps://metagenomi.co/
Ticker SymbolMGX
IPO dateFeb 09, 2024
CEOIrish (Jian)

Company Executives of Metagenomi Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Brian C. Thomas, Ph.D.
Dr. Brian C. Thomas, Ph.D.
Co-Founder, Director
Co-Founder, Director
2.43M
+1.46%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
598.72K
-0.36%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
598.72K
-0.36%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
598.72K
-0.36%
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
109.14K
-4.80%
Dr. Laurence E. Reid, Ph.D.
Dr. Laurence E. Reid, Ph.D.
Director
Director
20.00K
--
Dr. Laurence E. Reid, Ph.D.
Dr. Laurence E. Reid, Ph.D.
Director
Director
20.00K
--
Dr. Laurence E. Reid, Ph.D.
Dr. Laurence E. Reid, Ph.D.
Director
Director
20.00K
--
Dr. Juergen Eckhardt, M.D.
Dr. Juergen Eckhardt, M.D.
Independent Director
Independent Director
--
--
Dr. Willard H. (William) Dere, M.D.
Dr. Willard H. (William) Dere, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Brian C. Thomas, Ph.D.
Dr. Brian C. Thomas, Ph.D.
Co-Founder, Director
Co-Founder, Director
2.43M
+1.46%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
598.72K
-0.36%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
598.72K
-0.36%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
598.72K
-0.36%
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
109.14K
-4.80%
Dr. Laurence E. Reid, Ph.D.
Dr. Laurence E. Reid, Ph.D.
Director
Director
20.00K
--

FAQs

Who are the top five shareholders of Metagenomi Inc?

The top five shareholders of Metagenomi Inc are: Dr. Brian C. Thomas, Ph.D.

How many institutions hold shares of Metagenomi Inc (MGX)?

As of 2026Q1, 172 institutions hold shares of Metagenomi Inc, with a combined market value of approximately 8.82M, accounting for 23.43% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -6411264.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.